CLINICAL LETTER
Fatal fulminant inflammation in the diaphragm resulting from pembrolizumab-related myopathy
Graphical Abstract
The pathological investigations of the fatal fulminant inflammation in the diaphragm resulting from Pembrolizumab-related myopathy. Histologically, diaphragm demonstrated massive infiltration of inflammatory cells and muscle fiber necrosis.The mechanisms that explain the generation of PD-1 nyopathy are still unknown. We should therefore always pay close attention to the neuromuscular symptoms of patients treated with ICIs.
DISCLOSURE
Conflict of interest: The authors declare no conflict of interest. Human studies: Informed consent was obtained from the patient's family. Animal studies: No animals were used in this study.
